A Phase 1 open-label, first-in-human, multi-center, dose escalation and dose expansion study of CLN-619 administered alone or in combination with pembrolizumab in patients with advanced solid tumors.
CLN-619-001
Phase 1 other active
Quick answer
A Phase 1 open-label, first-in-human, multi-center, dose escalation and dose expansion study of CLN-619 administered alone or in combination with pembrolizumab in patients with advanced solid tumors. for Solid tumors, Non-Small Cell Lung Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer, breast cancer, gastrointestinal cancer is a Phase 1 program (other) at Cullinan Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Cullinan Therapeutics
- Indication
- Solid tumors, Non-Small Cell Lung Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer, breast cancer, gastrointestinal cancer
- Phase
- Phase 1
- Modality
- other
- Status
- active